Baird analyst Jack Allen is “incrementally positive” on this microcap biotech stock after Regeneron Pharmaceuticals (REGN) said it will be acquiring existing collaborator Checkmate Pharmaceuticals (CMPI) for $250M in an all-cash transaction. Should Regeneron continue… To see the rest of the story go to thefly.com. (See Story Here):(https://www.thefly.com/permalinks/entry.php/id3495895/-Street-expert-sees-over–upside-for-this-potential-biotech-MA-target)
previous post
next post